Conference Call on Interim Report July-September 2025
GOTHENBURG, SWEDEN, SE / ACCESS Newswire / October 13, 2025 /XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO 's conference call regarding the interim report July-September 2025. The presentation will be held in English.
Time: Thursday October 23, at 2.00 pm CET / 8.00 am EST
If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions. https://events.inderes.com/xvivo/q3-report-2025
If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions verbally. https://events.inderes.com/xvivo/q3-report-2025/dial-in
Participants from XVIVO:
Christoffer Rosenblad, CEO
Kristoffer Nordström, CFO
A press release containing XVIVO 's interim report July-September 2025 will be released on October 23, 2025 at 7.30 am CET / 1.30 am EST.
Before the conference call, slides will be available at the company web page, https://www.xvivogroup.com/investors/reports-and-presentations/
October 13, 2025
Mölndal
XVIVO Perfusion AB (publ)
For further information, please contact:
Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
Attachments
Conference call on Interim Report July-September 2025
SOURCE: XVIVO Perfusion AB
View the original press release on ACCESS Newswire
© 2025 ACCESS Newswire. All Rights Reserved.
